Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Common Stock Issued

Cash raised by issuing new shares.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued dips below year-ago levels

Q1 FY2026 common stock issued of $5K fell 88.1% year over year, behind the +213.9% change in trailing-twelve-month common stock issued. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +477.6% a year.

Context

  • Common stock issued amounted to 3740.4% of revenue in FY2025, up 1928.0 pp from a year earlier.
  • Common stock issued increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -88.1% toward the trailing-twelve-month pace of +213.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5K-100.0% QoQ
Last fiscal yearDec 2025
$61.08M+227.8% YoY
LTMMar 2026
$58.23M+213.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-88.1%——
1 year+227.8%——
3-year CAGR+477.6%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
61.08M USD
Year-over-year change
+227.8%
4-year CAGR
-4.6%

Common Stock Issued vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +213.9% is the 4th highest of 9, against a peer median of +98.9%.
  • Common stock issued amounts to 1837.6% of revenue for RANI, versus a peer median of 516.3%.
RANI Competitors
Common Stock Issued for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$196.51M USD-2.9%+36.1%1119.3%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$104.89M USD+75017.8%+219.2%5879.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$90.73M USD+439.2%-4.5%262.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$77.35M USD+115.3%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$58.23M USD+213.9%+477.6%1837.6%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$14.61M USD+34.0%+589.1%—
IPHAInnate Pharma S.A.FY2025€14.39M EUR+391.5%+317.3%516.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.66M USD-95.0%+225.3%506.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 73.01K CHF+82.5%-36.8%—
Peer median (excluding RANI) —+98.9%+219.2%516.3%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.